Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
City of Hope Medical Center
Pfizer
Institut Paoli-Calmettes
Guangdong Provincial People's Hospital
Abramson Cancer Center at Penn Medicine
Fudan University
University of Washington
Sichuan University
Sichuan University
Krystal Biotech, Inc.
University Hospital, Essen
Trans Tasman Radiation Oncology Group
Incyte Corporation
West China Hospital
Sun Yat-sen University
SWOG Cancer Research Network
University of Kentucky
Hoosier Cancer Research Network
Tang-Du Hospital
Shanghai Pulmonary Hospital, Shanghai, China
Second Affiliated Hospital of Guangzhou Medical University
Celldex Therapeutics
Swiss Cancer Institute
Shanghai University of Traditional Chinese Medicine
Zhejiang Cancer Hospital
Spectrum Pharmaceuticals, Inc
Abramson Cancer Center at Penn Medicine
H. Lee Moffitt Cancer Center and Research Institute
Ain Shams University
The First People's Hospital of Lianyungang
Bristol-Myers Squibb
Roswell Park Cancer Institute
Centre Francois Baclesse
Alliance for Clinical Trials in Oncology
ChineseAMS
AHS Cancer Control Alberta
University of Chicago
National Cancer Institute (NCI)
International Atomic Energy Agency
ChineseAMS
National Cancer Institute (NCI)
Pierian Biosciences
Genentech, Inc.
Roswell Park Cancer Institute
National Cancer Center, Korea
National Cancer Center, Korea
Pfizer
FeRx